Y. Karen Wang
Y. Karen Wang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Adarsh Godbole
Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
1 shared publicationAndrew A. Nguyen
Biotherapeutic and Analytical Technologies, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA 02139, USA
1 shared publicationBokang Rabasha
Broad Institute of Massachusetts Institute of Technology and Harvard Cambridge MA USA
1 shared publicationDale A Porter
Novartis Institute of Biomedical Research Cambridge MA USA
1 shared publicationDominique Forestier
Broad Institute of Massachusetts Institute of Technology and Harvard Cambridge MA USA
1 shared publicationE Robert McDonald
Novartis Institute of Biomedical Research Cambridge MA USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2021
- Published by Springer Nature in Molecular Systems Biology
- Vol. 17 (9) , e10156
A highly multiplexed quantitative phosphosite assay for biology and preclinical studies
Reliable methods to quantify dynamic signaling changes across diverse pathways are needed to better understand the effects of disease and drug treatment in cells and tissues but are presently lacking. Here, we present SigPath, a targeted mass spectrometry (MS) assay that measures 284 phosphosites in 200 phosphoproteins of biological interest. SigPath probes a broad swath of signaling biology with high throughput and quantitative precision. We applied the assay to investigate changes in phospho‐signaling in drug‐treated cancer cell lines, breast cancer preclinical models, and human medulloblastoma tumors. In addition to validating previous findings, SigPath detected and quantified a large number of differentially regulated phosphosites newly associated with disease models and human tumors at baseline or with drug perturbation. Our results highlight the potential of SigPath to monitor phosphoproteomic signaling events and to nominate mechanistic hypotheses regarding oncogenesis, response, and resistance to therapy.
- 1 September 2021
- Published by Springer Nature in Molecular Systems Biology
- Vol. 17 (9) , e10156
Open AccessA highly multiplexed quantitative phosphosite assay for biology and preclinical studies
Reliable methods to quantify dynamic signaling changes across diverse pathways are needed to better understand the effects of disease and drug treatment in cells and tissues but are presently lacking. Here, we present SigPath, a targeted mass spectrometry (MS) assay that measures 284 phosphosites in 200 phosphoproteins of biological interest. SigPath probes a broad swath of signaling biology with high throughput and quantitative precision. We applied the assay to investigate changes in phospho‐signaling in drug‐treated cancer cell lines, breast cancer preclinical models, and human medulloblastoma tumors. In addition to validating previous findings, SigPath detected and quantified a large number of differentially regulated phosphosites newly associated with disease models and human tumors at baseline or with drug perturbation. Our results highlight the potential of SigPath to monitor phosphoproteomic signaling events and to nominate mechanistic hypotheses regarding oncogenesis, response, and resistance to therapy.
- 1 July 2018
- Published by Elsevier in Protein Expression and Purification
- Vol. 147, 38-48
Full-length myocilin protein is purified from mammalian cells as a dimer
- 1 July 2018
- Published by Elsevier in Protein Expression and Purification
- Vol. 147, 38-48
Full-length myocilin protein is purified from mammalian cells as a dimer